A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients

Acta Gastro-Enterologica Belgica

Volumn 73, Issue 2, 2010, Pages 223-228

  Nevens, F ^a   van Vlierberghe, H ^b   D'Heygere, F ^c   Delwaide, J ^d   Adler, M ^e   Henrion, J ^f   Lenaerts, A ^g   Hendlisz, A ^h   Michielsen, P ⁱ   Bastens, B ^j   Laureys, A ^k   Brenard, B ^l  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c Dienst Gastro   (Belgium)

^d CHU SART TILMAN   (Belgium)

^e ERASME HOSPITAL   (Belgium)

^f Hospital de Jolimont   (Belgium)

^g Centre Hospitalier Universitaire de Charleroi   (Belgium)

^h JULES BORDET INSTITUTE   (Belgium)

ⁱ UZ Antwerpen   (Belgium)

^j Service d'Hepato Gastro   (Belgium)

^k Clinique Saint Joseph   (Belgium)

^l NV Roche SA   (Belgium)

more..

Author keywords

Chronic hepatitis c; Pegylated interferon; Relapse treatment; Slow viral response

Indexed keywords

PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; VIRUS RNA;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 77956637307     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. HADZIYANNIS S. J., SETTE H. JR., MORGAN T.R., BALAN V., DIAGO M., MARCELLIN P., RAMADORI G., BODENHEIMER H. JR., BERNSTEIN D., RIZZETTO M., ZEUZEM S., POCKROS P.J., LIN A., ACKRILL A.M; PEGASYS INTERNATIONAL STUDY GROUP. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepa-titis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med., 2004, 140: 346-355.
2. HERRINE S.K., BROWN R.S. JR., BERNSTEIN D.E., ONDOVIK M.S., LENTZ E., TE H. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. Dig. Dis. Sci., 2005, 50: 719-726.
3. JACOBSON I.M., GONZALEZ S.A., AHMED F., LEBOVICS E., MIN A.D., BODENHEIMER H.C. JR., ESPOSITO S.P., BROWN R.S. JR., BRÄU N., KLION F.M., TOBIAS H., BINI E.J., BRODSKY N., CERULLI M.A., AYTAMAN A., GARDNER P.W., GEDERS J.M., SPIVACK J.E., RAHMIN M.G., BERMAN D.H., EHRLICH J., RUSSO M.W., CHAIT M., ROVNER D., EDLIN B.R. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am. J. Gastroenterol., 2005, 100: 2453-2462.
4. SHERMAN M., YOSHIDA E.M., DESCHENES M., KRAJDEN M., BAIN V.G., PELTEKIAN K., ANDERSON F., KAITA K., SIMONYI S., BALSHAW R., LEE S.S; CANADIAN PEGASYS STUDY GROUP. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut, 2006, 55: 1631-1638.
5. BASSO M., TORRE F., GRASSO A., PERCARIO G., AZZOLA E., ARTIOLI S., BLANCHI S., PELLI N., PICCIOTTO A. Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. Dig. Liver Dis., 2007, 39: 47-51.
6. BROUWER J.T., NEVENS F., BEKKERING F.C., BOURGEOIS N., VAN VLIERBERGHE H., WEEGINK C.J., LEFEBVRE V., VAN HATTUM J., HENRION J., DELWAIDE J., HANSEN B.E., SCHALM S.W., FOR THE BENELUX STUDY GROUP ON TREATMENT OF CHRONIC HEPATITIS. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. J. Hepatol., 2004, 40: 689-695.
7. DE MAEGHT S., HENRION J., BOURGEOIS N., DE GALOSCY C., LANGLET P., MICHIELSEN P., REYNAERT H., ROBAEYS G., SPRENGERS D., ORLENT H., ADLER M. A pilot observational survey of hepatitis C in Belgium. Acta Gastroenterol. Belg., 2008, 71: 4-8.
8. MANNS M.P., MCHUTCHISON J.G., GORDON S.C., RUSTGI V.K., SHIFFMAN M., REINDOLLAR R., GOODMAN Z.D., KOURY K., LING M., ALBRECHT J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001, 358: 958-965.
9. BERG T., SARRAZIN C., HERRMANN E., HINRICHSEN H., GERLACH T., ZACHOVAL R., WIEDENMANN B., HOPF U., ZEUZEM S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology, 2003, 37: 600-609.
10. BUTI M., VALDES A., SANCHEZAVILA F., ESTEBAN R., LURIE Y. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology, 2003, 37: 1226-1227.
11. BERG T., VON WAGNER M., NASSER S., SARRAZIN C., HEINTGES T., GERLACH T., BUGGISCH P., GOESER T., RASENACK J., PAPE G.R., SCHMIDT W.E., KALLINOWSKI B., KLINKER H., SPENGLER U.,MARTUS P., ALSHUTH U., ZEUZEM S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferonalfa- 2a plus ribavirin. Gastroenterology, 2006, 130: 1086-1097.
12. SANCHEZTAPIAS J.M., DIAGO M., ESCARTIN P., ENRIQUEZ J., ROMEROGOMEZ M., BARCENA R., BÁRCENA R., CRESPO J., ANDRADE R., MARTÍNEZBAUER E., PÉREZ R., TESTILLANO M., PLANAS R., SOLÁ R., GARCÍABENGOECHEA M., GARCIASAMANIEGO J., MUÑOZSÁNCHEZ M., MORENOOTERO R; TERAVIC-4 STUDY GROUP. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology, 2006, 131: 451-460.